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Vascularized Bone Marrow Transplantation in Rats: Evidence for 
Amplification of Hematolymphoid Chimerism and Freedom From 
Graft-Versus-Host Reaction 
R. Llull. N. Murase, Q. Yeo R. Manez. A.J. Demetris, V. Fournier. and T.E. Starzl 
T HE PERSISTENCE of donor-derived leukocytes. 
which are capable of proliferating. trafficking, and 
interacting within the recipient tissues. has been proposed 
as a biological mechanism which facilitates the induction of 
acquired tolerance after whole organ transplantation. l Al-
though the details of the intrinsic mechanisms which un-
derlie the bidirectional immune modulation are unknown. 
it is speculated that augmentation of chimerism will favor 
graft acceptance and may eventually lead to a drug-free 
existence. 
Rat hind limb contains mature Iymphocvtes (regional 
lymph nodes). nonparenchymal tissue (skin and muscle), 
and vascularized bone marrow. which after transplantation 
provides a continuous supply of donor-derived progenitor 
cells. [n the present study. we compared the level of 
chimerism induced experimentally by either vascularized 
hone marrow transplantation (VBMTx) using the rat hind 
limb allograft model. or else bv infusion of t:ither lymph 
node or bone marrow cells. Their intiuence on the inci-
dence and severitv of graft-versus-host disease (GVHD) 
was also assessed. 
MATERIALS AND METHODS 
Animals and Transplant Procedures 
Male L~\vls (LEW: RT·JA /) and Brown Norwav IBN: RT·JA") rats. 
weighing 20U to 3()() g. purchased from Harlan Spraguc-Dawley 
(Indianapolis. Ind). were uscd as donors and recipients. respec-
lIvelv. 
OrthotopIC transplantation of hind limb allogratts was carned 
llut accordin\! to a proccdure described previously.; Brielly. osteo-
wnthcsis was pcrformed at the mldfemur level. followed hy end-
Ill-end anaSlOmmls of femoral vessels. repair ot the sCiatic nerve. 
approximation of thigh muscle. and skin closure. 
Bone marrow cells were ohtained by !Iushing the marrOW cavities 
llf donor f~murs and tihias. whereas. lymph node <:ells were 
rrepared hv gentle teasing In RPMI (Gihco BRL Grand Island. 
"IY). Cdl viability was determined by trypan blue exclusion which 
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\Vas routinely found to he >90%. Each recipient (BN) received via 
penile vein either 2.5 x 10M LEW bone marrow (BMTx) or lymph 
node (LNTx) cells. 
Immunosuppression 
Recipients were continuously maintained on FK 506 (Tacrolimus. 
Prograf'". Fujisawa Pharmaceutical Co. Ltd. Osaka. Japan) with 
daily intramuscular injection of 1.0 mg/kg from days 0 to 13. 
followed by weekly injections during the follow-up period (lOO 
days). 
Flow Cytometric Analysis 
Blood was taken from the recipients at various times after trans· 
plantation. Red blood cells were lysed by red cell lysis buffer (Sigma 
Chemical. St Louis. Mo) and lymphocytes were stained with MAl' 
163. which is specific for the RT- JA / antigen on LEW. or with MAl. 
~2. which is specific for the RT·JA" anugen on BN (these antibod· 
ies were generously provided by Dr H.W. Kunz. Department 01 
Pathology. University of Pittsburgh). A more detailed phenotype 01 
<:himeric cells was obtained by two-color !low cylOmetric analysis 
with MAhs specific for lymphocyte lineage markers. The following 
MAbs were purchased from Harlan Bioproducts for Science. Inc 
(Indianapolis. [nd): W3/25 (rat a-CD4 and a-macrophage). OX8 
(rat a-CDS and a-NK cells). and R73 (anti-apTCR). OX33 (rat 
,,·8 cells). Monoclonal antibody 3.2.3 (rat a-NK cells) was gener· 
'lusly provided hv Dr W. Chambers. (Pittsburgh Cancer Institute. 
Pittshurgh. Pcnn,. 
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VBMTx IN RATS 
Table 1. Animal Survival and Incidence of GVHD After 
Vascularized Bone Marrow (VBMTx) and Lymph Node (LNTx) 
and Bone Marrow (BMTx) Cell Transplant From LEW-BN 
GVHD (%) 
lypes 01 Animal Survival 
Alloorafts Mechan (days) Incidence MOI1allty 
VBMTx 6 >100 33.5 0 
LNTx 6 56.5 100 100 
BMTx 6 >100 a a 
RESULTS 
Recipient (BN) Survival and Incidence of GVHD 
Lethal GVHD ensued in all animals that received mature 
immunocyte infusion (LNTx) with a median survival of 56.5 
days (Tahlc I). None of the recipients treated with bone 
marrow cells (BMTx) demonstrated either clinical or his-
topatlwlogical evidence of GVHD and all survived for 
·100 davs (Tahle I). Interestingly. only 33.5 cr of VBMTx 
n:cipicms developed moderate yct self-limiting GVHD 
h,·twccn davs 50 and SO after transplantation. whereas the 
r,'mall1l11g animals were GVHD-free during the entire 
1"llow-lIp pcriod of 100 days (Table I). 
Flow Cytometry 
Very low levels of donor MHC class I-positive cells were 
dctcctahle in recipient PBMC after infusion of either BM 
or lymph node cells (Table 2). The percentage of donor 
cclls in the recipient PBMC was low (1 % to 2%) during the 
first month aftcr VBMTx; nevertheless. it gradually in-
creased to a higher level (2% to 6%) and remained 
consistently so throughout the period of immunosuppres-
sion (100 days). 
Whcn chimeric donor cells were tested with lineage-
'perilll' markers. we were able to detect T cells (a/3TCR +). 
1\ n:lI, (OX:;:; , ). and NK cells (3.2Y). Furthermore. in 
1\1\11\ .Illd VI3MTx recipients. no specific lineage was found 
to hc predominant: however. this was not true in recipients 
Teble 2. Characteristics of Donor-Cell Chimerism After 
VelCularized Bone Marrow (VBMTx) and Lymph Node (LNTx) 
end Bone Marrow (BMTx) Cell Transplant From LEW-BN 
TY\)II of Level of Characteristics of 
Allografts Chlmensm Chimeric Cells 
VSMTx 1.2-6.7% Multilineage 
LNTx 1-2% Predominantly T cell 
BMfx <1% Multilineage 
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of LNTx. in whom donor T cells were found to he in 
abundance (Table 2). 
Few donor MHC class II ~ (L21.6·) cells with dendritic 
morphology were found in the lymphoid tissues of BM-
transplanted GVHD-free animals. On the contrary. 
GVHD-prone LNTx and VBMTx recipients exhihited a 
very high frequency of donor class II' cells. 
It is of interest to note that after complete withdrawal of 
FK 506 (100 days posttransplant). VBMTx recipients dis-
played clinical and histopathological signs of chronic rejec-
tion (ie. atrophic skin. muscle contracture. and reduced 
nociperception). an observation paralleled hy disappear-
ance of circulating donor-derived cells in the recipients. 
DISCUSSION 
This study demonstrates that VBMTx can achieve a signif-
icant amplification of donor chimeric cells without the 
concomitant induction of lethal GVHD. The augmentation 
of donor leukocyte chimerism was best achieved with 
VBMTx. and only 33% of these animals subsequently 
developed GVHD. On the contrary. despite moderate 
levels of chimerism. LNTx recipients developed lethal 
GVHD and died with a median survival of 56 days. These 
observations suggest that phenotypic characteristics rather 
than the level of donor-cell chimerism dictate the emer-
gence of lethal GVHD. 
Since multilineage macrochimerism induced by VBMTx 
was associated with fewer incidences of self-limiting 
GVHD. it is tempting to speculate that the trafficking of 
progenitor cells from the graft into the recipient and the 
subsequent establishment of mixed chimerism might be the 
basis for attenuation of GVH responses.' It is noteworthy 
that the induction and perpetuation of donor-cell chimer-
ism was intimately associated with the well-being of the 
hind limb allograft. since termination of FK 506 therapy. 
which ushered in chronic rejection. closely shadowed the 
disappearance of donor-cell chimerism in the periphery. It 
remains to be ascertained if macrochimerism induced by 
VBMTx confers any functional advantage over microchi-
merism in achieving transplantation tolerance. 
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